REGULATORY

• MHLW Pharma Bureau Chief Eager to Do Everything on Regulation Panel’s Agenda
  July 25, 2023

• Label Expansions for Jakavi, Soliris in Line for Approval
  July 25, 2023

• Panel on Generic Industry to Boot Up July 31, Report Expected by Fall
  July 25, 2023

• Label Updated for ViiV’s 4 HIV Meds to Change Caution for Patients with Renal Dysfunctions
  July 24, 2023

• 93 Health Damages Reported for Temcell in Japan: October-March
  July 24, 2023

• Japan Embassy Granted First In-Person Visit to Detained Astellas Employee
  July 24, 2023

• Japan Might See COVID-19 Spike in Summer: Top Govt Spokesman
  July 24, 2023

• Tadayuki Mizutani Tapped as MHLW Director for Pharma Industry Promotion
  July 24, 2023

• Phase Out or Scrap Inflation Mitigation Measures: CEFP Members
  July 21, 2023

• Label Revisions Ordered for Xocova, Mounjaro to Add New ADR Risks
  July 21, 2023

• LDP Policy Panel OKs FY2024 Budget Guidelines, Social Security Wording Unchanged
  July 20, 2023

• Japan’s 1st Stelara, G-Lasta Biosimilars Nearing Finish Line
  July 18, 2023

• Perjeta/Herceptin SC Combo Up for MHLW Panel Review on July 31
  July 18, 2023

• Reflect Price and Wage Hikes in FY2024 Budget Guidelines, Lawmakers Urge
  July 18, 2023

• Relief Claims OK’ed for 6 More Deaths Possibly Tied to COVID Jabs
  July 18, 2023

• Japan Weighs Adoption of EMA Approach for Nitrosamine Impurities Risk Assessment
  July 14, 2023

• Japan Govt to Stockpile Xofluza for 1.44 Million People
  July 14, 2023

• Chuikyo OKs CEA Organization’s Reform Directions for FY2024
  July 13, 2023

• Chuikyo Reps Want More Data from Industry to Review Launch Premiums
  July 13, 2023

• Chuikyo Discusses Price Maintenance Premium, Focus Is on Company Criteria
  July 13, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 76
• 77
• 78
• 79
• 80
• 81
• 82
• 83
• 84
• …
• Next ›
• 最終 »